Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension.
Briot K, Portale AA, Brandi ML, Carpenter TO, Cheong HI, Cohen-Solal M, Crowley RK, Eastell R, Imanishi Y, Ing S, Insogna K, Ito N, Jan de Beur S, Javaid MK, Kamenicky P, Keen R, Kubota T, Lachmann RH, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Nixon A, Nixon M, Sun W, Williams A, Imel EA. Briot K, et al. Among authors: cheong hi. RMD Open. 2021 Sep;7(3):e001714. doi: 10.1136/rmdopen-2021-001714. RMD Open. 2021. PMID: 34548383 Free PMC article. Clinical Trial.
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period.
Portale AA, Carpenter TO, Brandi ML, Briot K, Cheong HI, Cohen-Solal M, Crowley R, Jan De Beur S, Eastell R, Imanishi Y, Imel EA, Ing S, Ito N, Javaid M, Kamenicky P, Keen R, Kubota T, Lachmann R, Perwad F, Pitukcheewanont P, Ralston SH, Takeuchi Y, Tanaka H, Weber TJ, Yoo HW, Zhang L, Theodore-Oklota C, Mealiffe M, San Martin J, Insogna K. Portale AA, et al. Among authors: cheong hi. Calcif Tissue Int. 2019 Sep;105(3):271-284. doi: 10.1007/s00223-019-00568-3. Epub 2019 Jun 4. Calcif Tissue Int. 2019. PMID: 31165191 Free article. Clinical Trial.
Burosumab vs conventional therapy in children with X-linked hypophosphatemia: results of the open-label, phase 3 extension period.
Ward LM, Högler W, Glorieux FH, Portale AA, Whyte MP, Munns CF, Nilsson O, Simmons JH, Padidela R, Namba N, Cheong HI, Sochett E, Muroya K, Tanaka H, Pitukcheewanont P, Gottesman GS, Biggin A, Perwad F, Chen A, Lawrence Merritt Ii J, Imel EA. Ward LM, et al. Among authors: cheong hi. JBMR Plus. 2024 Jan 4;8(1):ziad001. doi: 10.1093/jbmrpl/ziad001. eCollection 2024 Jan. JBMR Plus. 2024. PMID: 38690124 Free PMC article. Clinical Trial.
Genotype-phenotype correlations in children with Gitelman syndrome.
Cho MH, Park PG, Kim JH, Jang KM, Lee JM, Yang EM, Park SJ, Suh JS, Cho H, Lee JW, Lee JH, Koo JW, Namgoong MK, Kim KH, Ahn YH, Kang HG, Cheong HI. Cho MH, et al. Among authors: cheong hi. Clin Exp Nephrol. 2024 Mar 13. doi: 10.1007/s10157-024-02474-x. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 38478191
Development of a tool for predicting HNF1B mutations in children and young adults with congenital anomalies of the kidneys and urinary tract.
Kołbuc M, Kołek MF, Motyka R, Bieniaś B, Habbig S, Burgmaier K, Prikhodina L, Papizh S, Tasic V, Okorn C, Szczepańska M, Kiliś-Pstrusińska K, Wasilewska A, Adamczyk P, Tkaczyk M, Pańczyk-Tomaszewska M, Miklaszewska M, Pawlaczyk K, Bukowska-Olech E, Jamsheer A, Jankauskiene A, König J, Cheong HI, Ahn YH, Kaspar S, Sikora P, Beck BB, Zaniew M. Kołbuc M, et al. Among authors: cheong hi. Pediatr Nephrol. 2024 Jun;39(6):1847-1858. doi: 10.1007/s00467-023-06262-9. Epub 2024 Jan 10. Pediatr Nephrol. 2024. PMID: 38196016 Free PMC article. Clinical Trial.
Predicting Fatigue-Associated Aberrant Driving Behaviors Using a Dynamic Weighted Moving Average Model With a Long Short-Term Memory Network Based on Heart Rate Variability.
Tsai CY, Cheong HI, Houghton R, Hsu WH, Lee KY, Kang JH, Kuan YC, Lee HC, Wu CJ, Li LJ, Lin YT, Lin SY, Manole I, Majumdar A, Liu WT. Tsai CY, et al. Among authors: cheong hi. Hum Factors. 2024 Jun;66(6):1681-1702. doi: 10.1177/00187208231183874. Epub 2023 Jun 30. Hum Factors. 2024. PMID: 37387305
Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237.
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group. Ariceta G, et al. Kidney Int. 2023 Jul;104(1):205. doi: 10.1016/j.kint.2023.04.010. Kidney Int. 2023. PMID: 37349053 Free article. No abstract available.
250 results